Canada Gazette, Part I, Volume 153, Number 39: GOVERNMENT NOTICES

September 28, 2019

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant safety data sheet (SDS) and (where applicable) the label listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor, 4908B, Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015.

All claims for exemption in this publication were filed and evaluated in accordance with the provisions of WHMIS 2015.

A Notice of Filing was published in Part I of the Canada Gazette and there were no written representations from affected parties with respect to any of the claims for exemption and related SDSs or labels mentioned below.

Each of the claims for exemption listed in the table below was found to be valid except for that for Registry Number (RN) 9471, which was found to be partially valid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

RN	Claimant	Product Identifier	Date of Decision
9471	Exaltexx Inc.	Exalt-AMA-100	2019-02-15
9600	BYK USA Inc.	BYK-W 966	2019-05-03
9710	Multi-Chem Production Chemicals Co.	MC MX 1-1190	2019-06-13
9727	Multi-Chem Production Chemicals Co.	MC MX 924-5	2019-06-13
9824	Nalco Canada ULC	Torq Free™ HD	2019-05-30
9845	Nalco Canada ULC	3D TRASAR 3DT408	2019-06-04
9962	BYK USA Inc.	ANTI-TERRA-U 100	2019-05-03
10033	Innospec Fuel Specialties LLC	OGI-6140	2019-06-05
10035	Innospec Fuel Specialties LLC	OGI-4710	2019-07-26
10858	Nalco Canada ULC	AIM1010	2019-06-11
11130	Canadian Energy Services	Stimwrx-Poly-CI-A	2019-06-10
11266	BYK USA Inc.	ANTI-TERRA U	2019-05-03
11267	BYK USA Inc.	BYK-W 920	2019-05-03
11795	Suez Water Technologies& Solutions Canada	PETROFLO 20Y3108	2019-07-08
12100	Halliburton Group Canada	HpH Breaker	2019-06-21
12148	Nalco Canada ULC	3D TRASAR™ 3DT337	2019-07-18

The claimant name on which the screening officer issued a decision for the following claim is different from the claimant name that was published in the Notice of Filing.

RN	Notice of Filing Publication Date	Original Claimant Name	New Claimant Name
11795	2017-11-11	GE Water & Process Technologies Canada	Suez Water Technologies & Solutions Canada

The subject of the claim on which the screening officer issued a decision for the following claims is different from the subject of the claim that was published in the Notice of Filing.

RN	Notice of Filing Publication Date	Original Subject of the Claim	Revised Subject of the Claim
9845	2016-03-26	C.i. and C. of one ingredient C. of one ingredient	C.i. of one ingredient
10858	2017-01-28	C.i. and C. of three ingredients C. of two ingredients	C.i. of three ingredients

Note: C.i. = chemical identity and c. = concentration

In all cases where the SDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the SDS or the label amended as necessary.

Non-compliances that fall outside the scope of what is required to be published in the Canada Gazette are referred to as “administrative non-compliances.”

Please refer to Health Canada’s List of Active Claims for Exemption for a description of “administrative non-compliances” and their associated corrective measures.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant SDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.

RN: 9600

Date of compliance undertaking: 2019-07-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the Canadian initial supplier identifier.
2. Disclose the appropriate restrictions on use.
3. Disclose the appropriate first aid measures.
4. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
5. Disclose the product’s boiling range.
6. Disclose that the ingredient “naphtha (petroleum), heavy alkylate” has been shown to be an aspiration hazard.
7. Correct the disclosure of misleading information regarding skin corrosion/skin irritation.
8. Correct the disclosure of misleading information regarding serious eye damage/eye irritation.

RN: 9824

Date of compliance undertaking: 2019-07-11

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the information elements concerning the additional hazard and precautionary statements.
2. Remove CANUTEC’s emergency telephone number.
3. Disclose the additional hazard classification of “Eye Irritation — Category 2” and remove the health hazard classification of “Eye Irritation — Category 2B”.
4. Disclose the applicable common names and synonyms for the ingredients “isopropanol” and “diesel fuel No. 2”.
5. Disclose, in Section 3, which ingredients are part of a complex mixture and to which complex mixture they belong.
6. Disclose the product’s melting point and freezing point.
7. Disclose the product’s reactivity.
8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
9. Correct the precautionary statements to select the appropriate phrases when a slash is present.

RN: 9845

Date of compliance undertaking: 2019-07-11

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Remove CANUTEC’s emergency telephone number.
2. Disclose the information elements concerning the additional hazard and precautionary statements.
3. Disclose the applicable common names and synonyms for the ingredient “benzotriazol”.
4. Disclose the applicable information for “the most important symptoms and effects, whether acute or delayed” under Section 4, “First aid measures”.
5. Disclose statements conveying the relevant precautionary information in Section 4 of the SDS.
6. Disclose statements conveying the relevant precautionary information in Section 7 of the SDS.
7. Disclose an adequate product odour.
8. Disclose the product’s reactivity.
9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
10. Disclose the calculated product inhalation ATE value of 97.8 mg/L (22.4% unknown).
11. Disclose the likely routes of exposure in Section 11, “Toxicological Information”.
12. Correct the precautionary statements to select the appropriate phrases when a slash is present.

RN: 9962

Date of compliance undertaking: 2019-07-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the Canadian initial supplier identifier.
2. Disclose the appropriate first aid measures.
3. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
4. Disclose the product’s pH.
5. Disclose the product’s boiling range.
6. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.

RN: 10033

Date of compliance undertaking: 2019-07-19

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the additional hazard classifications of “Skin Sensitizer — Category 1A”, “Carcinogenicity — Category 1” and “Serious Eye Damage — Category 1” and remove the hazard classification of “Eye Irritation — Category 2A”.
2. Disclose the information elements concerning the additional hazard and precautionary statements.
3. Disclose the symbols and/or the name of symbols for “Health Hazard” and “Corrosion” on the SDS.
4. Disclose the signal word “Danger”.
5. Correct the disclosure of misleading information regarding first aid measures.
6. Correct the disclosure of misleading information regarding personal protective equipment in section 6, “Accidental release measures”.
7. Correct the disclosure of misleading information regarding precautions for safe handling.
8. Correct the disclosure of misleading information regarding appropriate engineering controls.
9. Disclose the ACGIH TLV–TWA of 0.1 ppm and ACGIH–STEL of 0.3 ppm exposure limits for the ingredient “formaldehyde”.
10. Disclose an adequate product odour.
11. Disclose the product’s boiling range.
12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
13. Disclose the calculated product oral ATE value of 18 750 mg/kg (40% unknown).
14. Clarify if the ingredient “phosphorous acid” is part of the product composition and disclose all relevant information about this ingredient in section 3 of the SDS.
15. Clarify if the ingredient “phosphorous acid” is part of the product composition and correct the disclosure of misleading information regarding the LD₅₀ (rat, oral) value for the confidential ingredient “phosphonic acid”.
16. Disclose the likely routes of exposure in section 11, “Toxicological Information”.
17. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
18. Remove the reference to HMIRC on the SDS.

RN: 10035

Date of compliance undertaking: 2019-08-22

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the additional information elements in the applicable SDS sections.
2. Disclose the Canadian initial supplier identifier.
3. Disclose the likely routes of exposure in section 11, “Toxicological Information”.
4. Disclose the symptoms related to the physical, chemical and toxicological characteristics.

RN: 10858

Date of compliance undertaking: 2019-07-25

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the additional hazard classifications of “Skin Corrosion — Category 1”, “Acute Toxicity (Inhalation) — Category 3” and “Acute Toxicity (Oral) — Category 4” and remove the hazard classification of “Skin Corrosion — Category 1B”.
2. Disclose the symbol and/or name of the symbol for “Skull and Crossbones” on the SDS.
3. Disclose the percent of unknown toxicity of “9.3%” and “55%” for the calculated product oral and inhalation ATE values, respectively.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Disclose the applicable information for “the most important symptoms and effects, whether acute or delayed” under section 4, “First aid measures”.
6. Disclose statements conveying the relevant precautionary information in section 4 of the SDS.
7. Disclose information on the precautions for firefighters.
8. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
9. Disclose the product’s boiling range.
10. Disclose the product’s reactivity.
11. Disclose “aluminum, hydrogen peroxide (oxidizer), 4-hydroxy-3-methoxybenzaldehyde, thallium 3 nitrate, nitric acid (acids), urea, nitromethane, palladium, phosphorous pentoxide, and sodium hypochlorite (oxidizer)” as incompatible materials.
12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
13. Disclose the calculated product oral ATE value of 1 692 mg/kg (9.3% unknown) and calculated inhalation (vapour) ATE value 9.8 mg/L (55% unknown).
14. Disclose the likely routes of exposure in section 11, “Toxicological Information”.
15. Correct the precautionary statements to select the appropriate phrases when a slash is present.

RN: 11130

Date of compliance undertaking: 2019-07-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Remove CANUTEC’s emergency telephone number.
2. Disclose the Canadian initial supplier identifier.
3. Disclose the additional hazard classification of “Specific Target Organ Toxicity — Repeated Exposure — Category 1”.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Disclose “Other hazards” on the SDS.
6. Disclose the applicable common names and synonyms for the ingredient “xylene”.
7. Disclose the incompatibilities of the product.
8. Disclose the delayed and immediate effects, as well as the chronic effects from short-term and long-term exposure.
9. Disclose the calculated product oral ATE value of 4 762 mg/kg (0% unknown) and calculated inhalation ATE value 29 mg/L (31% unknown).
10. Correct the disclosure of misleading information regarding the LD₅₀ (rat, oral) value and LC₅₀ (rat, inhalation [vapour]) value for the ingredient “xylene”.
11. Correct the precautionary statements to select the appropriate phrases when a slash is present.

RN: 11266

Date of compliance undertaking: 2019-07-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the Canadian initial supplier identifier.
2. Disclose the additional hazard classifications of “Reproductive Toxicity — Category 1” and “Specific Target Organ Toxicity — Repeated Exposure — Category 1 (central nervous system and hearing loss)”.
3. Disclose the signal word “Danger”.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Correct the precautionary statements to select the appropriate phrases when a slash is present.
6. Disclose the percent of unknown toxicity of “55%” for the calculated product inhalation ATE value.
7. Disclose the applicable common names and synonyms for the ingredients “xylene” and “isobutanol”.
8. Disclose the appropriate first aid measures.
9. Disclose the most important symptoms and effects, whether acute or delayed.
10. Correct the disclosure of misleading information regarding extinguishing media.
11. Disclose the appropriate precautions for safe handling.
12. Disclose the product’s melting point and freezing point.
13. Disclose the product’s boiling range.
14. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
15. Disclose the calculated product oral ATE value of 4 764 mg/kg (50.5% unknown) and calculated inhalation (vapour) ATE of 38 mg/L (55% unknown).
16. Correct the disclosure of misleading information regarding the LD₅₀ (rat, oral) and LC₅₀ (rat, inhalation) values for the ingredient “xylene”, and the LD₅₀ (rat, oral) and LC₅₀ (rat, inhalation) values for the ingredient “isobutanol”.

RN: 11267

Date of compliance undertaking: 2019-07-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Disclose the Canadian initial supplier identifier.
2. Disclose the additional hazard classifications of “Reproductive Toxicity — Category 1” and “Specific Target Organ Toxicity — Repeated Exposure — Category 1 (central nervous system and hearing loss)”.
3. Disclose the signal word “Danger”.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Correct the precautionary statements to select the appropriate phrases when a slash is present.
6. Disclose the percent of unknown toxicity of “55%” for the calculated product inhalation ATE value.
7. Disclose the applicable common names and synonyms for the ingredients “xylene” and “isobutanol”.
8. Disclose the appropriate first aid measures.
9. Disclose the most important symptoms and effects, whether acute or delayed.
10. Correct the disclosure of misleading information regarding extinguishing media.
11. Disclose the appropriate precautions for safe handling.
12. Disclose the product’s melting point and freezing point.
13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
14. Disclose the calculated product oral ATE value of 4 764 mg/kg (50.5% unknown) and calculated inhalation (vapour) ATE of 38 mg/L (55% unknown).
15. Correct the disclosure of misleading information regarding the LD₅₀ (rat, oral) and LC₅₀ (rat, inhalation) values for the ingredient “xylene”, and the LD₅₀ (rat, oral) and LC₅₀ (rat, inhalation) values for the ingredient “isobutanol”.

RN: 11795

Date of compliance undertaking: 2019-07-26

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
2. Disclose the additional hazard classification of “Acute Toxicity (Oral) — Category 4”.
3. Disclose the information elements concerning the additional hazard and precautionary statements.
4. Disclose the applicable common names and synonyms for the ingredient “hydroquinone”.
5. Correct the disclosure of misleading information regarding personal protective equipment in case of accidental release.
6. Disclose the appropriate precautions for safe handling.
7. Correct the disclosure of misleading information regarding personal protective equipment for precautions for safe handling.
8. Disclose the appropriate engineering controls.
9. Disclose an adequate product odour.
10. Disclose the calculated product oral ATE value of 1 750 mg/kg (0% unknown).

RN: 12148

Date of compliance undertaking: 2019-08-19

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
2. Remove CANUTEC’s emergency telephone number.
3. Disclose the additional hazard classifications of “Skin Corrosion — Category 1” and “Serious Eye Damage — Category 1”.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Disclose the symbol and/or name of the symbol for “Corrosion” on the SDS.
6. Disclose the signal word “Danger”.
7. Disclose the applicable common names and synonyms for the ingredient “benzotriazol”.
8. Disclose the applicable information for “the most important symptoms and effects, whether acute or delayed” under Section 4, “First aid measures”.
9. Disclose emergency procedures to follow in case of accidental release.
10. Correct the disclosure of misleading information regarding personal protective equipment in section 6, “Accidental release measures”.
11. Disclose the applicable information in Section 7, “Handling and storage”.
12. Disclose an adequate product odour.
13. Disclose the product’s reactivity.
14. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
15. Disclose the calculated product oral ATE value of 6 500 mg/kg (45.4% unknown) and calculated dermal ATE value of 6 500 mg/kg (45.4% unknown).
16. Disclose the likely routes of exposure in Section 11, “Toxicological Information”.

CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended SDS to the screening officer within 30 days of expiry of the appeal period.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the SDS reviewed by the screening officer and the date of the order.

RN: 9710

Date of order: 2019-07-18

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
2. Disclose the additional information elements in the applicable SDS sections.
3. Disclose the additional hazard classifications of “Specific Target Organ Toxicity — Repeated Exposure — Category 1” and “Flammable Liquids — Category 1”.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Disclose the applicable common names and synonyms for the ingredients “xylene”, “methanol” and “heavy aromatic petroleum naphtha”.
6. Disclose the product’s relative density.
7. Disclose the calculated product oral ATE value of 6 460 mg/kg, dermal ATE value of 12 000 mg/kg and inhalation (vapour) ATE value of 42 mg/L.
8. Correct the disclosure of misleading information regarding the LD₅₀ (rat, oral) and LD₅₀ (rabbit, dermal) value for the ingredients “xylene” and “heavy aromatic petroleum naphtha”, respectfully.

RN: 9727

Date of order: 2019-07-18

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
2. Disclose the Canadian initial supplier identifier.
3. Disclose the additional hazard classification of “Acute Toxicity (Inhalation) — Category 3”.
4. Correct the disclosure of misleading information regarding product hazard classification.
5. Disclose the symbol and/or name of symbol for “Skull and Crossbones” on the SDS.
6. Disclose the percent of unknown toxicity of “77%” for the calculated product inhalation ATE value.
7. Disclose the information elements concerning the additional hazard and precautionary statements.
8. Disclose the applicable common names and synonyms for the ingredients “light aromatic solvent”, “heavy aromatic petroleum naphtha”, “ethylene glycol monobutyl ether” and “isopropanol”.
9. Disclose the calculated product oral ATE value of 4 100 mg/kg (0% unknown), dermal ATE value of 2 700 mg/kg (0% unknown), and inhalation (vapour) ATE of 4.6 mg/L (77% unknown).
10. Correct the disclosure of misleading information regarding the LD₅₀/LC₅₀ values.
11. Disclose that ingredient “ethylene glycol monobutyl ether” has been shown to cause damage to organs via a single exposure.

RN: 12100

Date of order: 2019-07-25

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
2. Disclose the additional information elements in the applicable SDS sections.
3. Disclose the telephone number of the Canadian initial supplier identifier.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Disclose the additional information elements in the applicable SDS sections.
6. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
7. Disclose information on the precautions for firefighters.
8. Correct the disclosure of misleading information regarding personal protective equipment in section 6, “Accidental release measures”.
9. Disclose an adequate product odour.
10. Disclose the product’s boiling range.
11. Disclose “ingestion” as an additional likely route of exposure.
12. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
14. Disclose the calculated product oral ATE value of 26 000 mg/kg (0% unknown).
15. Correct the disclosure of misleading information regarding serious eye damage/eye irritation.

CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED THE DECISION THAT THE CLAIM FOR EXEMPTION WAS EITHER PARTIALLY VALID OR INVALID

In the case of the following claims, the screening officer issued the decision that the claim for exemption was partially valid.

Pursuant to section 18 of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an SDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant SDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 9471

Date of order: 2019-07-25

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

1. Remove the reference to HMIRC on the SDS.
2. Disclose the additional hazard classifications of “Serious Eye Damage — Category 1” and “Acute Toxicity (Inhalation) — Category 4 (dusts and mists)”.
3. Disclose the symbol and/or name of symbol for “Corrosion” on the SDS.
4. Disclose the information elements concerning the additional hazard and precautionary statements.
5. Disclose an acceptable TWA exposure guideline for the confidential ingredient “aliphatic hydrocarbon; acid (1)”.
6. Disclose the product’s odour threshold.
7. Disclose the boiling range, evaporation rate, flammability, upper and lower flammability or explosive limits, relative density, solubility, partition coefficient, and viscosity.
8. Disclose the calculated product oral ATE value of 4 600 mg/kg (0% unknown), dermal ATE value of 50 230 mg/kg (45% unknown), and inhalation (dusts and mists) ATE value of 4.4 mg/L (48% unknown.)

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Filing of claims for exemption

Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the filing of the claims for exemption listed below.

In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties, as defined, may make written representations to the screening officer with respect to the claim for exemption and the safety data sheet (SDS) or label to which it relates. Written representations must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor (4908-B), Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015.

The claims listed below seek an exemption from the disclosure of supplier confidential business information in respect of a hazardous product; such disclosure would otherwise be required under the provisions of the relevant legislation.

Claimant	Product Identifier	Subject of the Claim for Exemption	Registry Number
Shell Catalysts & Technologies	CENTERA GT ™ Catalyst DN-3622	C.i. and C. of one ingredient C.i. of two ingredients C. of one ingredient	03338074
Jacam Manufacturing, 2013, LLC	Cl BALLS Smart Balls® Corrosion Inhibitor	C.i. of one ingredient	03338133
Jacam Manufacturing, 2013, LLC	SP 3 Stim-Solv	C.i. of two ingredients	03338134
Jacam Manufacturing, 2013, LLC	SuperCorr® X Part B	C.i. of two ingredients	03338135
Baker Hughes Canada Company	CRW9952 CORROSION INHIBITOR	C.i. of seven ingredients C. of three ingredients	03338451
Baker Hughes Canada Company	RE34150CRW CORROSION INHIBITOR	C.i. of four ingredients C. of two ingredients	03338482
SUEZ Water Technologies & Solutions Canada	E.C.O.FILM EF2604	C.i. and C. of one ingredient	03338717
Stahl USA	RelcaLink 10	C.i. and C. of one ingredient C. of two ingredients	03338903
Globalquimica Partners LLC	RDV-01-CBP	C.i. and C. of one ingredient C. of two ingredients	03338905
PCT Global LLC	Enduroshield Professional	C.i. of one ingredient	03338994
PCT Global LLC	Enduroshield Auto Glass Professional	C.i. of one ingredient	03338995
Guardian Chemicals Inc.	CROSSOVER	C.i. and C. of four ingredients	03338996
Globalquimica Partners LLC	RDV-01 L	C.i. and C. of one ingredient	03339115
Allnex Canada Inc., c/o Goodmans, LLP	EBECRYL® 4510 radiation curing resins	C.i. and C. of one ingredient	03339191
Nalco Canada ULC	NALSIZE One 63242	C.i. of three ingredients	03339196
Nalco Canada ULC	NALSIZE One 63240	C.i. of three ingredients	03339197
Nalco Canada ULC	NALSIZE One 63243	C.i. of three ingredients	03339328
Fluid Energy Group Ltd.	Enviro-Syn® HCR-7000-WL	C.i. and C. of one ingredient	03339358
SUEZ Water Technologies & Solutions Canada	E.C.O.Film EF2401	C.i. and C. of one ingredient	03339595
DuPont Electronics & Imaging	Cyrel® Cylosol Component A	C.i. of one ingredient	03339693
DuPont Electronics & Imaging	Cyrel® Cylosol Component B	C.i. of one ingredient	03339694
Rampf Group Inc.	RAKU-FST RI-5501	C.i., C., and the toxicological study name of three ingredients C.i and C. of one ingredient and C.i of two ingredients	03339699
Gourley’s Auto Parts Ltd.	TARiffic Scent-Free Waterless Degreaser	C.i. and C. of four ingredients	03339960
Compass Minerals Manitoba Inc.	ROCKET SEEDS™ PMZ LIQUID 2-16-0	C.i. and C. of one ingredient	03339961
The Lubrizol Corporation	LUBRIZOL® 677A	C.i. of one ingredient	03339970
The Lubrizol Corporation	ANGLAMOL® 9001N	C.i. of two ingredients	03340086
Nouryon Surface Chemistry LLC	Redicote E-11E	C.i. of one ingredient	03340303
NCS Multistage	FFI 2000 M	C.i. of one ingredient	03340368
NCS Multistage	FFI 2100 M	C.i. of one ingredient	03340370
NCS Multistage	FFI 2200 M	C.i. of one ingredient	03340375
NCS Multistage	FFI 2300 M	C.i. of one ingredient	03340378
NCS Multistage	FFI 2400 M	C.i. of one ingredient	03340381
NCS Multistage	FFI 2700 M	C.i. of one ingredient	03340382
NCS Multistage	FFI 3000 M	C.i. of one ingredient	03340383
NCS Multistage	FFI 3200 M	C.i. of one ingredient	03340385
NCS Multistage	FFI 3300 M	C.i. of one ingredient	03340386
NCS Multistage	FFI 3400 M	C.i. of one ingredient	03340387
NCS Multistage	FFI 3500 M	C.i. of one ingredient	03340389
NCS Multistage	FFI 3600 M	C.i. of one ingredient	03340391
NCS Multistage	FFI 3700 M	C.i. of one ingredient	03340393
NCS Multistage	FFI 3800 M	C.i. of one ingredient	03340394
NCS Multistage	FFI 3900 M	C.i. of one ingredient	03340395
Nouryon Surface Chemistry LLC	Redicote C-320	C.i. of three ingredients	03340396
NCS Multistage	FFI 2500 M	C.i. of one ingredient	03340397
NCS Multistage	FFI 2600 M	C.i. of one ingredient	03340398
NCS Multistage	FFI 8300 M	C.i. of one ingredient	03340399
NCS Multistage	FFI 2900 M	C.i. of one ingredient	03340400
NCS Multistage	FFI 8100 M	C.i. of one ingredient	03340401
NCS Multistage	FFI 7000 M	C.i. of one ingredient	03340402
NCS Multistage	FFI 3100 M	C.i. of one ingredient	03340403
NCS Multistage	FFI 6400 M	C.i. of one ingredient	03340404
NCS Multistage	FFI 6300 M	C.i. of one ingredient	03340405
NCS Multistage	FFI 4100 M	C.i. of one ingredient	03340406
NCS Multistage	FFI 6200 M	C.i. of one ingredient	03340407
NCS Multistage	FFI 5300 M	C.i. of one ingredient	03340408
NCS Multistage	FFI 5200 M	C.i. of one ingredient	03340409
NCS Multistage	FFI 4200 M	C.i. of one ingredient	03340410
NCS Multistage	FFI 4300 M	C.i. of one ingredient	03340411
NCS Multistage	FFI 8400 M	C.i. of one ingredient	03340412
NCS Multistage	FFI 8500 M	C.i. of one ingredient	03340413
NCS Multistage	FFI 4500 M	C.i. of one ingredient	03340414
NCS Multistage	FFI 4600 M	C.i. of one ingredient	03340415
NCS Multistage	FFI 4700 M	C.i. of one ingredient	03340416
NCS Multistage	FFI 4800 M	C.i. of one ingredient	03340417
NCS Multistage	FFI 4900 M	C.i. of one ingredient	03340418
NCS Multistage	FFI 5000 M	C.i. of one ingredient	03340419
NCS Multistage	FFI 5100 M	C.i. of one ingredient	03340420
NCS Multistage	FFI 5400 M	C.i. of one ingredient	03340421
NCS Multistage	FFI 5500 M	C.i. of one ingredient	03340422

Note: C.i. = chemical identity and C. = concentration

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments
Name and position	Order in Council
Kenny, Leonard	2019-1322
Deputy Commissioner of Northwest Territories
Murphy, Brenda Louise	2019-1325
Lieutenant Governor of the Province of New Brunswick
Roy, Guylaine	2019-1329
Deputy Minister of Tourism, Official Languages and La Francophonie to be concurrently Deputy Minister of Women and Gender Equality
Williams, Rebekah Uqi	2019-1321
Deputy Commissioner of Nunavut

September 19, 2019

Diane Bélanger
Official Documents Registrar

DEPARTMENT OF TRANSPORT

CANADA MARINE ACT

Montreal Port Authority — Supplementary letters patent

WHEREAS letters patent were issued by the Minister of Transport (“Minister”) for the Montreal Port Authority (“Authority”), under the authority of the Canada Marine Act (“Act”), effective March 1, 1999;

WHEREAS section 9.2 of the letters patent sets out a limit on the power of the Authority to borrow money on its credit for port purposes;

WHEREAS the board of directors of the Authority has requested that the Minister issue supplementary letters patent to increase the aggregate limit on the power of the Authority to borrow money on the credit of the Authority for port purposes set out in section 9.2 of the letters patent;

WHEREAS, by Order in Council P.C. 2019-1326 of September 6, 2019, the Governor in Council, pursuant to subsection 8(5) of the Act, approved the provisions of the proposed supplementary letters patent for the purposes of increasing the aggregate limit on the power of the Authority to borrow money on the credit of the Authority for port purposes;

AND WHEREAS the Minister is satisfied that the amendment to the letters patent is consistent with the Act;

NOW THEREFORE, under the authority of subsection 9(1) of the Act, the letters patent are amended as follows:

1. Section 9.2 of the letters patent issued to the Montreal Port Authority is replaced by the following:
- 9.2 Limit on Borrowing Power. The Authority shall not incur any item of Borrowing so that the aggregate Borrowing of the Authority would exceed $420,000,000.
2. These supplementary letters patent take effect on January 1, 2020.

ISSUED this 11th day of September, 2019.

The Honourable Marc Garneau, P.C., M.P.
Minister of Transport

DEPARTMENT OF TRANSPORT

CANADA MARINE ACT

Montreal Port Authority — Supplementary letters patent

WHEREAS section 9.2 of the letters patent sets out a limit on the power of the Authority to borrow money on its credit for port purposes (“borrowing limit”);

WHEREAS the board of directors of the Authority has requested that the Minister issue supplementary letters patent to add two additional borrowing limits specific to identified projects thereby increasing the power of the Authority to borrow money on the credit of the Authority for port purposes set out in section 9.2 of the letters patent;

WHEREAS, by Order in Council P.C. 2019-1326 of September 6, 2019, the Governor in Council, pursuant to subsection 8(5) of the Act, approved the provisions of the proposed supplementary letters patent for the purposes of adding two additional borrowing limits specific to identified projects;

AND WHEREAS the Minister is satisfied that the amendment to the letters patent is consistent with the Act;

NOW THEREFORE, under the authority of subsection 9(1) of the Act, the letters patent are amended as follows:

1. The letters patent are amended by adding the following after section 9.2:
- 9.2.1 Additional Borrowing Limit for the rehabilitation of the Iberville Cruise Terminal and the Alexandra Pier. Notwithstanding section 9.2, the Authority may, in addition to the aggregate amount referred to in section 9.2, and the additional borrowing provided for in section 9.2.2, borrow up to a maximum of $20,000,000 on its credit, specifically for costs associated with the rehabilitation of the Iberville Cruise Terminal and the Alexandra Pier, provided such borrowing be fully reimbursable in capital and interest by the Province of Quebec pursuant to the agreement between Tourism Quebec and the Authority dated June 17, 2016, and amended August 6, 2018.
- 9.2.2 Additional Borrowing Limit for development and consolidation of port assets. Notwithstanding section 9.2, the Authority may, in addition to the aggregate amount referred to in section 9.2 and the additional borrowing provided for in section 9.2.1, borrow up to a maximum of $40,000,000 on its credit, specifically for costs associated with the development and consolidation of port assets, provided such borrowing be fully reimbursable in capital and interest by the Province of Quebec pursuant to the letters issued by the ministère des Transports, de la Mobilité durable et de l’Électrification des transports du Québec dated March 24, 2017, and August 1, 2017.
2. These supplementary letters patent take effect upon issuance.

ISSUED this 11th day of September, 2019.

The Honourable Marc Garneau, P.C., M.P.
Minister of Transport

DEPARTMENT OF TRANSPORT

CANADA MARINE ACT

Vancouver Fraser Port Authority — Supplementary letters patent

WHEREAS the Governor in Council issued a Certificate of Amalgamation containing letters patent to amalgamate the Vancouver Port Authority, the Fraser River Port Authority and the North Fraser Port Authority and to continue as one port authority named the Vancouver Fraser Port Authority (“Authority”), effective January 1, 2008;

WHEREAS Schedule C of the letters patent sets out the real property, other than federal real property, held or occupied by the Authority;

WHEREAS, pursuant to subsection 46(2.1) of the Canada Marine Act (“Act”), the Authority wishes to acquire the real properties bearing parcel identifiers (PID) 009-900-489 and 013-197-754;

WHEREAS the board of directors of the Authority has requested that the Minister of Transport issue supplementary letters patent to set out the real properties in Schedule C of the letters patent;

AND WHEREAS the Minister of Transport is satisfied that the amendments to the letters patent are consistent with the Act;

NOW THEREFORE, pursuant to subsection 9(1) of the Act, the letters patent are amended as follows:

1. Schedule C of the letters patent is amended by adding the following after PID 009-237-780:
PID NUMBER	DESCRIPTION
009-900-489	Lot 8, Block 30, District Lot 204, Plan 1340; As shown on Plan 1340 and Sketch Plan No. S2018-180
013-197-754	Parcel "B" (Reference Plan 4663), Fractional Section 19, Block 5 North, Range 2 West, New Westminster District, except: Firstly: Part 208.2 m² (Bylaw Plan 58239); Secondly: Part on Statutory Right of Way Plan LMP20327; As shown on Sketch Plan No. S2019-060

2. These supplementary letters patent take effect on the date of registration of the title, in the New Westminster Land Title Office, of each parcel of land subject to these transactions.

ISSUED this 29th day of August, 2019.

The Honourable Marc Garneau, P.C., M.P.
Minister of Transport

OFFICE OF THE SUPERINTENDENT OF FINANCIAL INSTITUTIONS

ASSESSMENT OF PENSION PLANS REGULATIONS

Basic rate

Notice is hereby given, in accordance with section 5 of the Assessment of Pension Plans Regulations, that the Superintendent of Financial Institutions sets the basic rate, established pursuant to section 4 of the said Regulations, at $10.00 for the Office year beginning on April 1, 2020. In accordance with subsection 1(1) of the said Regulations, this rate applies to all pension plans registered under the Pension Benefits Standards Act, 1985 and the Pooled Registered Pension Plans Act.

September 16, 2019

Judy Cameron
Acting Assistant Superintendent

BANK OF CANADA

Statement of financial position as at August 31, 2019

(Millions of dollars) Unaudited
ASSETS	Amount	Total
Cash and foreign deposits		22.0
Loans and receivables
Securities purchased under resale agreements	10,908.9
Advances	—
Other receivables	3.8
		10,912.7
Investments
Treasury bills of Canada	27,570.3
Canada Mortgage Bonds	513.7
Government of Canada bonds	79,849.3
Other investments	439.9
		108,373.2
Capital assets
Property and equipment	597.8
Intangible assets	50.9
Right-of-use leased assets	52.4
		701.1
Other assets		44.0
Total assets		120,053.0

LIABILITIES AND EQUITY	Amount	Total
Bank notes in circulation		90,801.4
Deposits
Government of Canada	25,139.6
Members of Payments Canada	250.0
Other deposits	2,583.2
		27,972.8
Securities sold under repurchase agreements		—
Other liabilities		747.0
		119,521.2
Equity
Share capital	5.0
Statutory and special reserves	125.0
Investment revaluation reserve	401.8
		531.8
Total Liabilities and Equity		120,053.0

I declare that the foregoing statement is correct according to the books of the Bank.

Ottawa, September 18, 2019

Carmen Vierula
Chief Financial Officer and Chief Accountant

I declare that the foregoing statement is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, September 18, 2019

Stephen S. Poloz
Governor